268 related articles for article (PubMed ID: 17705230)
21. Proteomics-based identification of biomarkers for predicting sensitivity to a PI3-kinase inhibitor in cancer.
Akashi T; Nishimura Y; Wakatabe R; Shiwa M; Yamori T
Biochem Biophys Res Commun; 2007 Jan; 352(2):514-21. PubMed ID: 17137555
[TBL] [Abstract][Full Text] [Related]
22. Use of surface enhanced laser desorption/ionization-time of flight mass spectrometry (SELDI-TOF MS) to study protein expression in a rat model of cocaine withdrawal.
Geng T; Seitz PK; Thomas ML; Xu B; Soman KV; Kurosky A; Luxon BA; Cunningham KA
J Neurosci Methods; 2006 Nov; 158(1):1-12. PubMed ID: 16766040
[TBL] [Abstract][Full Text] [Related]
23. Identification of a 17-protein signature in the serum of lung cancer patients.
Sreseli RT; Binder H; Kuhn M; Digel W; Veelken H; Sienel W; Passlick B; Schumacher M; Martens UM; Zimmermann S
Oncol Rep; 2010 Jul; 24(1):263-70. PubMed ID: 20514471
[TBL] [Abstract][Full Text] [Related]
24. Identification of proteins in laser-microdissected small cell numbers by SELDI-TOF and Tandem MS.
Kwapiszewska G; Meyer M; Bogumil R; Bohle RM; Seeger W; Weissmann N; Fink L
BMC Biotechnol; 2004 Dec; 4():30. PubMed ID: 15579198
[TBL] [Abstract][Full Text] [Related]
25. Characterization of apolipoprotein A-I as a potential biomarker for cholangiocarcinoma.
Wang X; Dai S; Zhang Z; Liu L; Wang J; Xiao X; He D; Liu B
Eur J Cancer Care (Engl); 2009 Nov; 18(6):625-35. PubMed ID: 19486127
[TBL] [Abstract][Full Text] [Related]
26. Application of serum SELDI proteomic patterns in diagnosis of lung cancer.
Yang SY; Xiao XY; Zhang WG; Zhang LJ; Zhang W; Zhou B; Chen G; He DC
BMC Cancer; 2005 Jul; 5():83. PubMed ID: 16029516
[TBL] [Abstract][Full Text] [Related]
27. Detection and identification of potential biomarkers of breast cancer.
Fan Y; Wang J; Yang Y; Liu Q; Fan Y; Yu J; Zheng S; Li M; Wang J
J Cancer Res Clin Oncol; 2010 Aug; 136(8):1243-54. PubMed ID: 20237941
[TBL] [Abstract][Full Text] [Related]
28. [Use of laser capture microdissection and surface-enhanced laser desorption ionization time-of-flight mass spectrometry to screen differential proteins in lung adenocarcinoma and lung squamous carcinoma].
Tian YX; Yang SY; Nan YD; Zhang W; Zhou B; Bu LN; Huo SF; Yu JK; Zheng S
Zhonghua Yi Xue Za Zhi; 2008 Jan; 88(3):145-8. PubMed ID: 18361807
[TBL] [Abstract][Full Text] [Related]
29. Profiling protein markers associated with lymph node metastasis in prostate cancer by DIGE-based proteomics analysis.
Pang J; Liu WP; Liu XP; Li LY; Fang YQ; Sun QP; Liu SJ; Li MT; Su ZL; Gao X
J Proteome Res; 2010 Jan; 9(1):216-26. PubMed ID: 19894759
[TBL] [Abstract][Full Text] [Related]
30. SELDI-TOF serum proteomics and colorectal cancer: a current overview.
Gemoll T; Roblick UJ; Auer G; Jörnvall H; Habermann JK
Arch Physiol Biochem; 2010; 116(4-5):188-96. PubMed ID: 20615064
[TBL] [Abstract][Full Text] [Related]
31. Discovery of serum protein biomarkers for prostate cancer progression by proteomic analysis.
Al-Ruwaili JA; Larkin SE; Zeidan BA; Taylor MG; Adra CN; Aukim-Hastie CL; Townsend PA
Cancer Genomics Proteomics; 2010; 7(2):93-103. PubMed ID: 20335524
[TBL] [Abstract][Full Text] [Related]
32. SELDI-TOF MS versus prostate specific antigen analysis of prospective plasma samples in a nested case-control study of prostate cancer.
Skytt A; Thysell E; Stattin P; Stenman UH; Antti H; Wikström P
Int J Cancer; 2007 Aug; 121(3):615-20. PubMed ID: 17410539
[TBL] [Abstract][Full Text] [Related]
33. MALDI-MS Protein Profiling of Chemoresistance in Extracellular Vesicles of Cancer Cells.
Stübiger G; Nairn MD; Abban TK; Openshaw ME; Mancera L; Herzig B; Wuczkowski M; Senfter D; Mader RM
Anal Chem; 2018 Nov; 90(22):13178-13182. PubMed ID: 30383359
[TBL] [Abstract][Full Text] [Related]
34. Proteomic Protocol in Esophageal Adenocarcinoma.
Kelly P
Methods Mol Biol; 2018; 1756():281-293. PubMed ID: 29600378
[TBL] [Abstract][Full Text] [Related]
35. MALDI mass spectrometry in prostate cancer biomarker discovery.
Flatley B; Malone P; Cramer R
Biochim Biophys Acta; 2014 May; 1844(5):940-9. PubMed ID: 23831156
[TBL] [Abstract][Full Text] [Related]
36. Surface-enhanced laser desorption/ionization time of flight mass spectrometry protein profiling identifies ubiquitin and ferritin light chain as prognostic biomarkers in node-negative breast cancer tumors.
Ricolleau G; Charbonnel C; Lodé L; Loussouarn D; Joalland MP; Bogumil R; Jourdain S; Minvielle S; Campone M; Déporte-Fety R; Campion L; Jézéquel P
Proteomics; 2006 Mar; 6(6):1963-75. PubMed ID: 16470659
[TBL] [Abstract][Full Text] [Related]
37. Strategy for purification and mass spectrometry identification of SELDI peaks corresponding to low-abundance plasma and serum proteins.
Fertin M; Burdese J; Beseme O; Amouyel P; Bauters C; Pinet F
J Proteomics; 2011 Apr; 74(4):420-30. PubMed ID: 21184852
[TBL] [Abstract][Full Text] [Related]
38. The use of laser microdissection and SELDI-TOF MS in ovarian cancer tissue to identify protein profiles.
Cadron I; Van Gorp T; Amant F; Vergote I; Moerman P; Waelkens E; Daemen A; Van De Plas R; De Moor B; Zeillinger R
Anticancer Res; 2009 Apr; 29(4):1039-45. PubMed ID: 19414343
[TBL] [Abstract][Full Text] [Related]
39. Discovery of diagnostic biomarkers for pancreatic cancer in immunodepleted serum by SELDI-TOF MS.
Xue A; Gandy RC; Chung L; Baxter RC; Smith RC
Pancreatology; 2012; 12(2):124-9. PubMed ID: 22487522
[TBL] [Abstract][Full Text] [Related]
40. Surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF MS) for determining prognosis in advanced stage hormone relapsing prostate cancer.
Kohli M; Siegel E; Bhattacharya S; Khan MA; Shah R; Suva LJ
Cancer Biomark; 2006; 2(6):249-58. PubMed ID: 17264396
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
